{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T21:17:46Z","timestamp":1787779066008,"version":"build-2784847793"},"reference-count":42,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jacl.2026.06.008","type":"journal-article","created":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T18:51:03Z","timestamp":1781463063000},"page":"1571-1581","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recurrence of cardiovascular events despite achieving LDL-C &lt;1.4\u00a0mmol\/L in patients with coronary artery disease"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6307-5593","authenticated-orcid":false,"given":"Yu","family":"Kataoka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kitahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Katasako-Yabumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayaka","family":"Funabashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Mitsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5162-4783","authenticated-orcid":false,"given":"Kota","family":"Murai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamasa","family":"Iwai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0710-0870","authenticated-orcid":false,"given":"Kenichiro","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Matama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2706-4317","authenticated-orcid":false,"given":"Masashi","family":"Fujino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Yoneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9009-7234","authenticated-orcid":false,"given":"Yasuhide","family":"Asaumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruo","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2026.06.008_bib1","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2026.06.008_bib2","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170\u2008000 participants in 26 randomised trials","volume":"376","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2026.06.008_bib3","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.06.008_bib4","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2026.06.008_bib5","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2026.06.008_bib6","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1161\/CIRCULATIONAHA.122.063399","article-title":"Association between achieved low-density lipoprotein cholesterol levels and long-term cardiovascular and safety outcomes: an analysis of FOURIER-OLE","volume":"147","author":"Gaba","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.06.008_bib7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.06.008_bib8","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.06.008_bib9","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1253\/circj.CJ-19-0133","article-title":"JCS 2018 guideline on diagnosis and treatment of acute coronary syndrome","volume":"83","author":"Kimura","year":"2019","journal-title":"Circ J"},{"key":"10.1016\/j.jacl.2026.06.008_bib10","doi-asserted-by":"crossref","first-page":"846","DOI":"10.5551\/jat.GL2017","article-title":"Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017","volume":"25","author":"Kinoshita","year":"2018","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jacl.2026.06.008_bib11","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1253\/circj.CJ-21-1041","article-title":"JCS 2022 guideline focused update on diagnosis and treatment in patients with stable coronary artery disease","volume":"86","author":"Nakano","year":"2022","journal-title":"Circ J"},{"key":"10.1016\/j.jacl.2026.06.008_bib12","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jacc.2011.09.077","article-title":"Functional measurement of coronary stenosis","volume":"59","author":"Pijls","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.06.008_bib13","first-page":"e18","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Lawton","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.06.008_bib14","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/aje\/kwk052","article-title":"Relaxing the rule of ten events per variable in logistic and Cox regression","volume":"165","author":"Vittinghoff","year":"2007","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jacl.2026.06.008_bib15","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1016\/j.jacc.2010.01.050","article-title":"Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol","volume":"55","author":"Bayturan","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.06.008_bib16","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jcmg.2021.11.014","article-title":"Determinants of plaque progression despite very low low-density lipoprotein-cholesterol levels with the PCSK9 inhibitor, evolocumab","volume":"15","author":"Honda","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jacl.2026.06.008_bib17","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.jacc.2010.02.026","article-title":"Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome","volume":"55","author":"Nicholls","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.06.008_bib18","doi-asserted-by":"crossref","first-page":"e185239","DOI":"10.1001\/jamanetworkopen.2018.5239","article-title":"Polyvascular disease and risk of major adverse cardiovascular events in peripheral artery disease: a secondary analysis of the EUCLID trial","volume":"1","author":"Gutierrez","year":"2018","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacl.2026.06.008_bib19","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.amjcard.2024.04.037","article-title":"Impact of polyvascular disease in patients undergoing unprotected left main percutaneous coronary intervention","volume":"222","author":"Bay","year":"2024","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2026.06.008_bib20","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.amjcard.2018.09.014","article-title":"Prevalence and outcomes of polyvascular (coronary, peripheral, or cerebrovascular) disease in patients with diabetes mellitus (from the SAVOR-TIMI 53 trial).","volume":"123","author":"Gutierrez","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2026.06.008_bib21","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.jacc.2010.10.034","article-title":"Peripheral arterial disease and progression of coronary atherosclerosis","volume":"57","author":"Hussein","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.06.008_bib22","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1161\/CIRCULATIONAHA.118.035432","article-title":"Lipoprotein particle profiles, standard lipids, and peripheral artery disease incidence","volume":"138","author":"Aday","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.06.008_bib23","doi-asserted-by":"crossref","first-page":"e005077","DOI":"10.1161\/JAHA.116.005077","article-title":"Inflammatory biomarkers interleukin-6 and C-reactive protein and outcomes in stable coronary heart disease: experiences from the STABILITY trial","volume":"6","author":"Held","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2026.06.008_bib24","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1001\/jama.2010.1322","article-title":"Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis","volume":"304","author":"Bhatt","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2026.06.008_bib25","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/eurheartj\/ehp099","article-title":"Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes","volume":"30","author":"Bhatt","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.06.008_bib26","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jacc.2019.03.013","article-title":"Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES trial","volume":"74","author":"Jukema","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.06.008_bib27","doi-asserted-by":"crossref","first-page":"100624","DOI":"10.1016\/j.lanepe.2023.100624","article-title":"Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study","volume":"29","author":"Ray","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.jacl.2026.06.008_bib28","doi-asserted-by":"crossref","DOI":"10.1093\/eurjpc\/zwaf388","article-title":"International patterns in lipid management and implications for patients with coronary heart disease: results from the INTERASPIRE study","author":"Brandts","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2026.06.008_bib29","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.atherosclerosis.2021.08.035","article-title":"Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study","volume":"334","author":"Vrablik","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2026.06.008_bib30","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.jacc.2023.02.018","article-title":"Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616","volume":"81","author":"Ballantyne","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.06.008_bib31","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/j.jacc.2025.03.499","article-title":"An oral PCSK9 inhibitor for treatment of hypercholesterolemia: the PURSUIT randomized trial","volume":"85","author":"Koren","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.06.008_bib32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1056\/NEJMoa2415820","article-title":"Safety and efficacy of obicetrapib in patients at high cardiovascular risk","volume":"393","author":"Nicholls","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2026.06.008_bib33","doi-asserted-by":"crossref","first-page":"e70010","DOI":"10.1002\/prp2.70010","article-title":"Obicetrapib exhibits favorable physiochemical and pharmacokinetic properties compared to previous cholesteryl ester transfer protein inhibitors: an integrated summary of results from non-human primate studies and clinical trials","volume":"12","author":"Nicholls","year":"2024","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.jacl.2026.06.008_bib34","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jacc.2025.07.056","article-title":"Impact of obicetrapib on major adverse cardiovascular events in high-risk patients:\u00a0a pooled analysis","volume":"86","author":"Nicholls","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.06.008_bib35","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2026.06.008_bib36","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1001\/jamacardio.2023.5155","article-title":"Impact of bempedoic acid on total cardiovascular events: a prespecified analysis of the CLEAR outcomes randomized clinical trial","volume":"9","author":"Nicholls","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacl.2026.06.008_bib37","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehag446","article-title":"Lipoprotein(a) and residual cardiovascular risks in japanese patients with coronary artery disease who achieve guideline recommended LDL-C goals","author":"Kataoka","year":"2026","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.06.008_bib38","doi-asserted-by":"crossref","DOI":"10.1253\/circj.CJ-25-0889","article-title":"Prognostic value of serum lipoprotein(a) levels in japanese patients with ST-segment elevation myocardial infarction","author":"Nishiyama","year":"2026","journal-title":"Circ J"},{"key":"10.1016\/j.jacl.2026.06.008_bib39","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1253\/circj.CJ-24-0383","article-title":"Impact of high lipoprotein(a) levels on delayed wound healing in patients with chronic limb-threatening ischemia after peripheral endovascular therapy","volume":"89","author":"Tomoi","year":"2025","journal-title":"Circ J"},{"key":"10.1016\/j.jacl.2026.06.008_bib40","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1253\/circj.CJ-23-0221","article-title":"Impact of lipoprotein (a) on long-term outcomes in patients with acute myocardial infarction","volume":"87","author":"Dai","year":"2023","journal-title":"Circ J"},{"key":"10.1016\/j.jacl.2026.06.008_bib41","doi-asserted-by":"crossref","first-page":"e016683","DOI":"10.1161\/CIRCIMAGING.124.016683","article-title":"Association of lipoprotein(a) with changes in coronary atherosclerosis in patients treated with alirocumab","volume":"17","author":"Koskinas","year":"2024","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jacl.2026.06.008_bib42","doi-asserted-by":"crossref","DOI":"10.1093\/eurjpc\/zwag036","article-title":"Indirect comparison of statin-ezetimibe and statin-PCSK9 inhibitor combination therapies for coronary artery plaque regression in acute coronary syndrome","author":"Yamashita","year":"2026","journal-title":"Eur J Prev Cardiol"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193328742600396X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193328742600396X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:22:34Z","timestamp":1787775754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S193328742600396X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S193328742600396X"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2026.06.008","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recurrence of cardiovascular events despite achieving LDL-C <1.4\u00a0mmol\/L in patients with coronary artery disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2026.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}